title: Neoadjuvant docetaxel/cyclophosphamide in triple-negative breast cancer: predictive value of class III-β tubulin and non-basal subtype.
abstract: OBJECTIVE
  We aimed to clarify which breast cancer subtypes respond best to docetaxel/cyclophosphamide chemotherapy (TC) as neoadjuvant chemotherapy (NAC).
  
  
  METHODS
  We analyzed pathological responses, clinicopathological characteristics and biological markers (estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor-2 (HER-2), Ki-67, p53, topoisomerase IIα, class III β tubulin, cytokeratin 5/6, epidermal growth factor receptor (EGFR)) in specimens from 79 patients who received NAC-TC.
  
  
  RESULTS
  Out of 79 patients, 33 (41.8%) achieved quasipathological complete responses (QpCR). Univariate analysis associated negative ER (p<0.001), negative PR (p=0.007), triple-negative subtype (TNBC; p=0.001), high Ki-67 (p=0.022) and low class III β tubulin (p=0.032) with QpCR. Multivariate analyses associated only negative ER (p=0.050) and low class III β tubulin (p=0.028) and only non-basal subtype in TNBC with QpCR.
  
  
  CONCLUSIONS
  NAC-TC may be especially effective in ER-breast cancer with low class III β tubulin or non-basal TNBC.
authors: Department of Breast and Thyroid Surgery, Yokohama City University Medical Center, Yokohama, Japan kazu90052003@yahoo.co.jp.
authors: Kazuhiro
authors: K
authors: Shimada
authors: Department of Breast and Thyroid Surgery, Yokohama City University Medical Center, Yokohama, Japan.
authors: Takashi
authors: T
authors: Ishikawa
authors: Department of Breast and Thyroid Surgery, Yokohama City University Medical Center, Yokohama, Japan.
authors: Kumiko
authors: K
authors: Kita
authors: Department of Breast and Thyroid Surgery, Yokohama City University Medical Center, Yokohama, Japan.
authors: Kazutaka
authors: K
authors: Narui
authors: Department of Breast and Thyroid Surgery, Yokohama City University Medical Center, Yokohama, Japan.
authors: Sadayoshi
authors: S
authors: Sugae
authors: Department of Breast and Thyroid Surgery, Yokohama City University Medical Center, Yokohama, Japan.
authors: Daisuke
authors: D
authors: Shimizu
authors: Department of Surgical Pathology, Yokohama City University Medical Center, Yokohama, Japan.
authors: Mikiko
authors: M
authors: Tanabe
authors: Department of Surgical Pathology, Yokohama City University Medical Center, Yokohama, Japan.
authors: Takeshi
authors: T
authors: Sasaki
authors: Department of Clinical Oncology, Yokohama City University Graduate School of Medicine, Yokohama, Japan.
authors: Takashi
authors: T
authors: Chishima
authors: Department of Clinical Oncology, Yokohama City University Graduate School of Medicine, Yokohama, Japan.
authors: Yasushi
authors: Y
authors: Ichikawa
authors: Department of Clinical Oncology, Yokohama City University Graduate School of Medicine, Yokohama, Japan.
authors: Itaru
authors: I
authors: Endo
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000378:metabolism*; D017024:Chemotherapy, Adjuvant; D003520:Cyclophosphamide / Q000008:administration & dosage; D000077143:Docetaxel; D005260:Female; D006801:Humans; D008875:Middle Aged; D043823:Taxoids / Q000008:administration & dosage; D064726:Triple Negative Breast Neoplasms / Q000188:drug therapy* / Q000378:metabolism; D014404:Tubulin / Q000378:metabolism*
chemical_list: D014408:Biomarkers, Tumor; D043823:Taxoids; D014404:Tubulin; D000077143:Docetaxel; D003520:Cyclophosphamide
keywords: Breast cancer; cyclophosphamide; docetaxel; neoadjuvant chemotherapy; predictive factor; triple-negative